



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC,
Phase 4, Ankleshwar – 393 002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India
Tel : (91-22) 26701050 / 1 / 2 / 3
Email: contact@samratpharmachem.in

August 13, 2021

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, August 13, 2021, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2021, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 13:00 hrs and concluded at 14:45 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat
Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2021

(Rupees in Lakhs)

Particulars	Quarter Ended		Year Ended	
	30-Jun-21 (Unaudited)	31-Mar-21 (Audited)	30-Jun-20 (Unaudited)	31-Mar-21 (Audited)
1 (a). Revenue from Operations	4,723.65	4,741.26	3,526.67	17,901.78
(b). Other Income	15.53	32.12	1.90	46.28
Total Revenue	4,739.18	4,773.38	3,528.57	17,948.06
2. Expenditure				
a) Cost of materials consumed	4,495.81	4,291.36	2,698.36	16,201.76
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	-65.16	64.01	574.69	222.75
d) Employee Costs	38.02	44.27	27.64	149.80
e) Interest	17.43	17.48	45.89	127.67
f) Depreciation & Amortisation expense	14.49	13.47	11.20	49.29
g) Other Expenses	112.81	146.99	64.25	460.64
(i) Manufacturing Expenses	89.44	78.84	50.09	286.50
(ii) Administration Expenses	13.91	26.01	8.76	72.44
(iii) Selling & Distribution Expenses	9.46	42.14	5.40	101.70
Total Expenses	4,613.40	4,577.58	3,422.03	17,211.91
3. Profit before exceptional & extraordinary items & tax	125.78	195.80	106.54	736.15
4. Exceptional Items	0.00	-1.77	0.00	-1.77
5. Profit before extraordinary items & tax	125.78	194.03	106.54	734.38
6. Extraordinary items	0.00	0.00	0.00	0.00
7. Profit before tax	125.78	194.03	106.54	734.38
8. Tax expense				
a) Current Tax	-29.83	-41.65	-10.65	-172.29
b) Deferred Tax	-0.60	3.59	-16.09	-28.78
Total Tax Expense	-30.43	-38.06	-26.74	-201.07
9. Profit (Loss) for the period after tax	95.35	155.97	79.80	533.31
10. Other Comprehensive Income (OCI)				
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	95.35	155.97	79.80	533.31
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
13. Earnings per equity share				
a) Basic	3.09	5.05	2.58	17.26
b) Diluted	3.09	5.05	2.58	17.26


Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2021
- The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Friday, 13 August 2021 at the Corporate Office of the Company.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.

Place : Mumbai
Date : 13 August 2021



By order of the Board of Directors
For Samrat Pharmachem Limited


Rajesh Mehta

Executive Director
DIN: 00216731



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance

CA Nihar Dharod
Indirect Tax & Litigation


Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

**The Board of Directors,
Samrat Pharmachem Limited.**

1. We have reviewed the accompanying statement of unaudited financial results of Samrat Pharmachem Limited, for the Quarter ended 30th June, 2021 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid applicable Indian Accounting Standards ('Ind AS') specifies under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Shah & Savla LLP
Chartered Accountants**

Firm Reg: No.: 109364W/W100143


CA. Miral H. Nagda
(Partner)

Membership No.: 108135
UDIN: 21108135AAAACL4815

Place: Mumbai

Date: 13th August, 2021

